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  ABSTRACT 
  Heparin has been shown to antagonize myotoxic effects of crotaline venoms. Here a very low heparin 
concentration (LHC) was examined in its ability to antagonize the neurotoxic/myotoxic effects of   Bothrops 
jararacussu   venom and its phospholipase A  2   myotoxin, bothropstoxin-I (BthTX-I), in an   in vitro   nerve-
muscle preparation and in mice gastrocnemius. Normalization of results was done by assays with commercial 
antibothropic antivenom (CBA). LHC (1  IU/ml) added to the incubation bath reduced by 4- and 4.5-fold 
(  vs   2.8- and 2.5-fold by CBA) the neuromuscular paralysis, by 5.4 and 4.4-fold (  vs   2.5- and 13.3-fold by CBA) 
the percentage of ﬁ  bers damaged and by 6- and 1.7-fold ( vs  30- and 1.6-fold by CBA) the CK activity induced by 
  B. jararacussu   and BthTX-I, respectively. Protamine sulphate added 15 min after the incubation of the prepara-
tion with LHC+venom, avoided the LHC neutralizing effect against venom neurotoxicity. This strongly attests 
that given the polycationic nature of protamine, it probably complexed with the polyanionic heparin making it 
unattainable for binding to basic components of venom, reducing toxicity. Since heparin antagonism is gener-
ally stronger against venom effects than is myotoxin we discuss that other venom components than the BthTX-I 
are likely target for the antagonism promoted by the polyanionic heparin.   
  KEYWORDS:  Antagonism ,   neuromuscular    junction ,   neutralization ,   protamine    
   INTRODUCTION 
  Bothrops jararacussu   snake venom has been studied since 
the early 1900s (  Brazil, 1909  ) and its myotoxic action has 
been well documented. The notion that the venom presents 
also neurotoxic activity has come from frog nerve-muscle 
  in vitro   studies done over 25 years ago (  Rodrigues-
Simioni et al, 1983  ). Bothropstoxin-I (BthTX-I), a Lys49 
PLA  2   (lysine in position 49) from   B. jararacussu   venom 
(Homsi-Brandeburo et al, 1988), considered its major toxin 
reproduces the myotoxic and neurotoxic effects of the venom 
(  Rodrigues-Simioni et al, 1983  ; Homsi-Brandeburo et al, 
1988), and both actions are probably partners in producing 
the severe effects of   B. jararacussu   envenoming (  Milani-
Junior et al, 1997  ;   Ribeiro and Jorge, 1997  ). 
  Strategies for minimizing the severe tissue damage at the 
snakebite site, in which antivenom therapy has been unsuc-
cessful, have been hastened in recent years (  Kanashiro et al, 
2002  ;   Soares et al, 2004  ;   Doin-Silva et al, 2008  ). Heparin is 55
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  Animals 
  Male Swiss white mice (25-30  gm) were supplied by the 
Animal Services Unit of the State University of Campinas 
(UNICAMP). The animals were housed at 25 ± 3   o  C on a 12 hr 
light/dark cycle and had access to food and water   ad libi-
tum  . This work was approved by the University Committee 
for Ethics in Animal Experimentation (CEEA/Institute of 
Biology, UNICAMP, Protocol 792-1) and the experiments 
were done in accordance with the guidelines established by 
the Brazilian College for Animal Experimentation (COBEA).  
  Evaluation  of  neurotoxicity 
  Phrenic nerve-diaphragm preparations (  Bülbring, 1946  ) 
(PND) were obtained from mice anesthetized with halotan 
(Cristália, Campinas, SP, Brazil) and killed by exsanguina-
tion. The diaphragm was removed and mounted under a 
tension of 5 gm in a 5 ml organ bath containing Tyrode solu-
tion (pH 7.4, 37°C) with the following composition (mM): 
NaCl 137; KCl 2.7; CaCl  2   1.8; MgCl  2   0.49; NaH  2 PO 4   0.42; 
NaHCO  3   11.9 and glucose 11.1, aerated with 95% (v/v) 
O  2   and 5% (v/v) CO  2  . Supramaximal stimuli (4x thresh-
olds, 0.1 Hz, 0.2 ms) delivered from a Grass S48 stimulator 
(Astro-Med Inc, W Warwick, RI, USA) were applied to the 
nerve through bipolar electrodes. Isometric muscle tension 
was recorded by a force displacement transducer (Load Cell 
BG-10 GM, Kulite Semiconductor Products Inc, NJ, USA) 
coupled to a physiograph (Gould, Model RS 3400) via a 
Gould universal ampliﬁ  er (both from Gould Inc, Recording 
Systems Division, Cleveland, OH, USA). The preparations 
were allowed to stabilize for at least 20 min before addition 
of either 40  µg/ml Bjssu, 2.9  µM BthTX-I, LHC, 5  IU/ml, 
CAB, 120 µl/ml, or with a mixture of venom:LHC (40 µg/ml:
5 IU/ml) or BthTX-I:LHC (2.9 µM:5 IU/ml), and venom:CBA 
(40 µg/ml:120 µl/ml),  BthTX-I:CBA  (2.9 µM:120 µl/ml), 
and observed for 120  min. Preparations using the mixtures 
venom/toxin plus LHC/CBA were preincubated at 37  o C  for 
30 min before the onset of experiments. Control experiments 
were done with Tyrode solution alone. Some protocols aim-
ing to evaluate the venom- or toxin-heparin binding were 
carried out using protamine sulfate (0.8  IU/ml), a heparin-
antagonist, 15  min after addition to bath of a preincubated 
(30 min at 37ºC) venom:LHC (40 µg/ml:5 IU/ml) mixture.   
  Evaluation  of  myotoxicity 
    Histological and morphometric analysis 
  At the end of each experiment, the mouse phrenic nerve-
diaphragm muscle preparation was rapidly removed from the 
bath and ﬁ  xed in Bouin’s ﬂ  uid for 24-48  hr. After washing 
in distilled water, ethanol series dehydration and Historesin 
embedding (Leica Instruments Gmbh, Nubloch/Heidelberg, 
Germany) sections 2  µm thick were obtained (Leika RM 
2035 microtome) and stained with 0.5% (w/v) toluidine blue 
(Vetec, SP, Brazil) in 5% (w/v) borax (Quimesp, SP, Brazil) 
for examination by light microscopy (LM). The extension 
of muscle damage was assessed by counting the number of 
ﬁ  bers with alterations (edema, darkening, sarcolemmal dis-
ruption and myoﬁ  brils lysis) and the ﬁ  gures were expressed 
as percentage of the total number of cells counted in 
three non-overlapping, non-adjacent areas of each muscle 
(  Oshima-Franco et al, 2001  ). The formula for calculating the 
% of damaged ﬁ  bers was %F = [(%f x 100)/Tf) - 100, where 
%f is the number of ﬁ  bers affected by venom or toxin and 
Tf is the total number of ﬁ  bers (affected and non-affected) 
a natural anticoagulant molecule whose acidic nature poten-
tially allows its interaction with basic phospholipases A  2 .  
In vivo   study demonstrated that pre-incubation of heparin 
with two crotalid venoms (from   Agkistrodon contortrix 
laticinctus   and   Crotalus viridis viridis   snakes) or their 
myotoxins antagonizes signiﬁ   cantly the myotoxicity of 
them (  Melo and Ownby, 1999  ). Other studies have shown 
that heparin is able to antagonize   in vitro   the release of 
creatine kinase (CK) and lactodehydrogenase (LDH) from 
muscle incubated with   Bothrops jararacussu   snake venom 
or its major myotoxin, bothropstoxin-I (BthTX-I) (  Melo 
and Suarez-Kurtz, 1988a  ;   Melo et al, 1993  ) resulting in 
reduction of the myotoxic effects. Previously,   Oshima-
Franco et al (2001)   reported that heparin at a concentra-
tion of 60 IU/ml was not able to signiﬁ  cantly antagonize the 
myotoxic effect of BthTX-I, but produced a 100% protec-
tion against neuromuscular blockade. Whether the antago-
nizing action of heparin against myotoxicity reported in 
literature and interpreted as is due to acid-basic complexes 
formation is also unclear. 
  In this study, these two open questions were revisited. In 
this context, the concentration of heparin was drastically 
reduced to 1 IU/ml to avoid the facilitatory effect which had 
been observed with 60 IU/ml (  Oshima-Franco et al, 2001  ). 
By using this approach, we investigated if the heparin anti-
neurotoxic effect still persisted and/or if the anti-myotoxic 
effect reported by other authors became apparent; further-
more, we used protamine sulfate, which like heparin is an 
anticoagulant drug, but that differently is cationic in nature 
instead of anionic like heparin is. By using this approach 
we evaluated whether the beneﬁ  ts brought about by heparin 
were due to formation of acid-basic complexes (heparin + 
basic venom components) or not. 
  For comparative purposes the antibothropic natural effect 
of heparin was assessed in parallel with the one produced 
by the commercial antibothropic serum against the myo-
toxicity induced by   B. jararacussu   venom and BthTX-I in 
mouse phrenic nerve-diaphragm preparation (  in vitro   study) 
or after intramuscular injection in mouse gastrocnemius 
(  in vivo   study).  
  MATERIALS AND  METHODS 
  Materials 
  B. jararacussu   venom (Bjssu) was provided by Insti-
tuto Butantan (São Paulo, SP, Brazil); BthTX-I was 
puriﬁ   ed from   B. jararacussu   venom as described 
by   Homsi-Brandeburgo et al (1988)  , and modiﬁ  ed  by 
Cintra et al (1993). Brieﬂ  y, crude venom was gel ﬁ  ltered 
on Sephadex G-75 and the catalytic active fraction SIII 
was re-chromatographed on SP-Sephadex C-25. BthTX-I 
(a Lys49-PLA  2   analogue, catalytically inactive, last 
eluting fraction) was dialyzed and lyophilized. Heparin - 
Liquemine® (25000  IU/ml – B1019) and Protamine 
1000® (lot 701811 151) were purchased from Roche (Rio 
de Janeiro, RJ, Brazil); Commercial Bothropic Antivenom 
(CBA) (FUNED – lot 030611-12) was kindly donated by 
the Escritório Regional de Saúde (ERSA) from Piracicaba 
(SP, Brazil); Creatine kinase (CK) CK-NAC Bioclin kit 
(lot 099) was purchased from Quibasa Química Básica Ltd 
(Belo Horizonte, MG, Brazil).   56
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incubation (120 min). The neutralization assays (  Figure 1B   
and   1C  ) showed that the neuromuscular paralysis induced 
by venom and toxin were signiﬁ  cantly attenuated (  P   < 0.05) 
changing to 20 ± 6% (n = 6) and 21 ± 7% (n = 8), respectively, 
if incubated with LHC and to 32  ±  6% (n  =  6) and 38  ±  6% 
(n = 6), respectively, if incubated with CBA at the end of the 
120 min incubation. 
      Protamine abolished neutralization of neuromuscular 
blockade promoted by heparin 
    Figure 1D   shows that 20  µl protamine (corresponding 
to 0.8  IU/ml) added 15  min after incubation of PND with 
Bjssu:LHC mixture prevented the antagonistic action of 
heparin against the neuromuscular blockade induced by 
Bjssu, which persisted even after washing the prepara-
tion. No signiﬁ  cant difference was seen in the time elapsed 
to achieve neuromuscular paralysis caused Bjssu alone 
(88 ± 2%; n = 6) and when protamine was prior added to the 
bath containing the mixture Bjssu+heparin (94 ± 4%; n = 6)   
    Heparin neutralized the morphological changes 
produced by Bjssu and BthTX-I in the diaphragm 
    Figure 2   shows light micrographs of diaphragm incubated 
with Tyrode solution,   B. jararacussu   venom or BthTX-I 
and with pre-incubation either with heparin or commercial 
antibothropic serum. In all set of experiments ﬁ  bers in dif-
ferent stages of necrosis as well normal ﬁ  bers were present. 
Swollen darkened ﬁ  bers predominated but ﬁ  bers contain-
ing densely clumped myoﬁ  brils, or compacted masses of 
myoﬁ  brils intermingled with diffuse amorphous areas of 
sarcoplasm were present. The percentage of ﬁ  bers with mor-
phological alterations was: Tyrode control (8%), LHC alone 
(7%), CBA alone (7%), Bjssu (27%) and BthTX-I (40%), 
(  P   < 0.05). Pre-incubation of LHC or CBA with venom or 
BthTX-I signiﬁ  cantly reduced the percentage of affected 
ﬁ  bers in such a way that there was no statistic difference in 
relation to preparations incubated with Tyrode solution or 
with either LHC or CBA alone. Heparin reduced to a greater 
degree the percentage of ﬁ  bers affected by venom than did 
in the section. This procedure was used in all experiments 
(controls and treated preparations, n = 3/each).   
    Measurement of CK release 
  Since CK release can not be measured in hemidiaphragm 
preparations, matched-  in vivo   groups of animals as for 
  in vitro   protocols of venom [(40  µg/ml), toxin (2.9  µM), 
venom:LHC (40 µg/ml:5 IU/ml), toxin:LHC (2.9 µM:5 IU/ml), 
venom:antivenom (40 µg/ml:120 µl/ml), and toxin:antivenom 
(2.9  µM:120  µl/ml)] were utilized to measure the plasma 
CK levels after injection in mouse gastrocnemius muscle. 
Two hours after injection, animals blood was collected from 
tail vein, stored in heparinized capillary tubes, centrifuged 
(3000xg, 3 min), and the plasma CK levels were determined 
using a diagnostic kit (CK-NAC Bioclin®). The CK activity 
was expressed as international units per liter (IU/L), where 
1 unit is the amount of enzyme which catalyses the trans-
formation of 1 µmol of creatine/min at 37  o C.  
  Statistical  analysis 
  Each experimental protocol was repeated from three to eight 
times and the results reported as the mean ± SEM were 
used for statistical comparison using ANOVA (Repeated 
Measures) followed by post-hoc Tukey test with a value of   
P  < 0.05 indicating signiﬁ   cance.    
  RESULTS 
    Heparin neutralized the neuromuscular blockade 
induced by Bjssu and BthTX-I 
  The graphic proﬁ   les of the preparations treated with 
Tyrode solution (control, n  =  4), LHC (5  IU/ml, n  =  6) and 
CBA (120  µl/ml, n  =  6) are represented in   Figure 1A  . Only 
the preparation treated with CBA alone showed an initial 
and marked facilitatory response represented by increased 
twitch-tension in all experiments, which was signiﬁ  cantly 
different from Tyrode control (  P  < 0.05).   Figures  1B   and   1C  
show the preparations treated with 40 µg/ml Bjssu or 2.9 µM 
BthTX-I,  which  presented  88 ± 2%  (n = 6)  and  95 ± 1.3% 
(n = 8), respectively, of neuromuscular blockade at the end of 
   Figure 1.       A.   Controls of Tyrode solu-
tion, LHC and CBA on mouse phrenic 
nerve-diaphragm preparations, indirectly 
stimulated.   B   and   C.   Bjssu and BthTX-I 
neuromuscular action and its neutrali-
zation by LHC or CBA, respectively. 
  D  . Neuromuscular effects induced by 
protamine: Its neutralizing effect on 
venom:LHC mixture was likely due to 
complexation of protamine and heparin, 
therefore leaving Bjssu free for induc-
ing its characteristic neuromuscular 
blockade. LHC, low heparin concen-
tration; Bjssu,   Bothrops jararacussu   
venom; BthTX-I, bothropstoxin-I. The 
points represent the mean ± SEM of 
the number of experiments indicated in 
parentheses. (*  P  < 0.05, when compared 
to control).      57
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venom:CBA mixtures showed a signiﬁ   cant shift of CK 
activity which dropped to 236 ± 40 (n = 6) and 47 ± 5 (n = 6,  
P   < 0.05 compared to control), respectively. Interestingly, 
both the heparin and commercial antiserum were not as 
efﬁ  cient in reducing the CK released by the Lys49 PLA  2  
myotoxin (BthTX-I) as they were for the venom. Pre-
incubation with LHC or CBA reduced to 900  ±  149 (n  =  5) 
and 935  ±  135 (n  =  5), respectively, the plasma CK levels 
in comparison to the observed with BthTX-I alone (1531 ± 
166). However, these values were signiﬁ  cantly  different 
from those obtained with BthTX-I alone (  P   < 0.05). 
          DISCUSSION 
  Neurotoxicity 
  The present ﬁ  ndings showed that when 1  IU/mL heparin 
is added to the venom- or bothropstoxin-containing bath 
the paralyzing effect was reduced by 4- and 4.5-fold, 
respectively. In comparison, when CBA is added to bath 
the commercial antiserum, as follows, 5% of ﬁ  bers affected 
in Bjssu:LHC mixture and 11% in Bjssu:CBA mixture; 
a lesser efﬁ  ciency had heparin in protecting against the pure 
myotoxin,   i.e.  , 9% of affected ﬁ  bers incubated in BthTX-I:
LHC mixture and 3% in BthTX-I:CBA mixture (  P   > 0.05). 
         Heparin neutralized the CK release from mouse 
gastrocnemius injected with Bjssu or BthTX-I 
  To co-validate the antagonizing effect of heparin and antise-
rum against venom-and pure myotoxin serum CK release 
was measured at 120 min after being injected in gastrocne-
mius.   Figure 3   shows the serum CK activity (CK release). 
The basal CK activity (IU/l) was 104 ±10 (n = 6) for saline 
control 119 ± 6 for LHC and 150 ± 13 for CBA, which were 
signiﬁ  cantly different from the elevated 1454  ±  185 (n  =  6) 
and 1531 ± 166 (n = 5) levels seen after Bjssu and BthTX-I 
injection, respectively. In contrast, the animals that received 
intramuscular (im) injection, either with venom:LHC or 
  Figure 3.     Measurement  of  plasmatic  CK 
release, 120 min after saline, Bjssu, BthTX-I 
or Bjssu+LHC; BthTX-I+LHC; Bjssu+CBA, 
or BthTX-I+CBA injection in mouse 
gastrocnemius. CK, creatine kinase; LHC, 
low heparin concentration; CBA, commercial 
bothropic antivenom; Bjssu,   Bothrops jara-
racussu   venom; BthTX-I, bothropstoxin-I. 
(*  P   < 0.05 = signiﬁ  cant difference in relation 
to saline control, **signiﬁ  cant difference in 
relation to Bjssu and BthTX-I). The values 
represent the mean ± SEM of the number of 
experiments (n = 5). 
  Figure 2.      Light  micrograph  show-
ing the histological appearance of 
diaphragm preparation after 120 min 
of indirect electrical stimulation and 
incubation in: (  A )  Tyrode  Solution, 
(  B  ) LHC 1 IU/ml, (  C  ) CBA 120 µl/ml, 
(  D  ) Bjssu 40 µg/ml, (  E )  Bjssu:LHC, 
(  F  ) Bjssu:CBA, (  G  ) BthTX-I 2.9 µM, 
(  H  ) BthTX-I:LHC and (  I )  BthTX-
I:CBA. Note the protection promoted by 
LHC and CBA against the myotoxicity 
induced by Bjssu and BthTX-I. LHC, 
low heparin concentration; CBA, 
commercial bothropic antivenom; 
Bjssu,   Bothrops jararacussu   venom; 
BthTX-I, bothropstoxin-I.   58
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evidences on the existence of some pre-synaptic action of   
B. jararacussu   venom (  Rodrigues-Simioni et al, 1983  ). 
  This study does not give a clear explanation on how and 
why only low concentration of heparin (1  IU/ml) was able 
to antagonize the neuromuscular blocking effect evoked by 
Bjssu or BthTX-I. However, since heparin has a large thera-
peutic use in numerous disease conditions, such possibility 
should not be neglected. We can speculate that the highly-
negative charge density of heparin contributes to attract 
positively-charged counterions of synaptic molecules, 
including that of AChE (through its collagen tail ColQ), 
thus promoting the neuro-protection. Either another possi-
ble explanation would be the heparin binding to components 
of venom and/or myotoxin, so neutralizing the expression 
of venom/toxin neurotoxicity. This latter possibility has 
been suggested to explain the heparin antagonism against 
myotoxicity of crotalid venoms, and was attributed to the 
anionic   vs.   cationic character of heparin   vs.   venom/toxin, 
respectively (  Melo and Suarez-Kurtz, 1988b  ;   Melo et al, 
1993  ;   Melo and Ownby, 1999  ).   
  Myotoxicity 
  In this regard, the mechanisms behind the anti-myotoxic 
effect of heparin have been stated as ought to: 1) the forma-
tion of acid-base complexes with basic myotoxins present 
in   Bothrops   venoms  ( Melo  and  Suarez-Kurtz,  1988a ;   Melo 
and Suarez-Kurtz, 1988b  ;   Melo et al, 1993  ;   Lomonte et al, 
1994a  ;   Lomonte et al, 1994b  ;   Angulo et al, 2001  ) and/or to 
2) the inﬂ  uence of heparin on PLA  2   present in many snake 
venoms (  Lomonte et al, 1994b  ;   Gutiérrez and Lomonte, 
2003  ), affecting (  Diccianini et al, 1990  ) or not (  Condreas 
and Vries, 1964  ), the enzymatic activity of these proteins. 
In the present study, we demonstrated that differently from 
high concentration of heparin (60  IU/ml) (  Oshima-Franco 
et al, 2001 ), a very low concentration (1 IU/ml) shows capac-
ity to antagonize the myotoxicity caused by   B. jararacussu  
venom and its main myotoxin in   in vitro   (morphometry 
of muscle damage) and   in vivo   (CK release) experiments. 
Thus, heparin is more effective in its antagonizing myotoxic 
effect against venom than against the myotoxin we can sug-
gest that other venom components than the BthTX-I basic 
PLA  2   are likely target for the antagonism promoted by the 
polyanionic heparin. 
  In fact, besides phospholipases A  2  , other venom com-
ponents, such as metalloproteinases, serino proteases, 
among others (  Gutiérrez and Lomonte, 1995  ;   Gutiérrez and 
Rucavado, 2000 ) contribute to muscle damage, and could also 
be target for heparin neutralization. Damage is initiated as a 
consequence of loss of ﬁ  ber sarcolemma integrity, followed 
by calcium inﬂ  ux and the forthcoming degenerative incomes 
comprising myoﬁ   lament hypercontraction, mitochondrial 
alterations, activation of endogenous phospholipases and 
calcium-dependent proteases which amplify the muscle-
damaging process (  Gutiérrez and Lomonte, 2003  ). Concomi-
tantly, it is launched an inﬂ  ammatory response with release 
and activation of pro-inﬂ   ammatory cytokines and other 
mediators, including nitric oxide, which could contribute to 
worsening the envenoming picture (  Zamuner et al, 2005  ). 
  Heparin is a member of the glycosaminoglycan (GAG) 
family of carbohydrates, which includes the closely-related 
the paralyzing effect is reduced in 2.8- and 2.5-fold, respec-
tively. There was not neurotransmission facilitation with this 
heparin concentration, differently from the ﬁ  ndings with 
60  IU/ml (  Oshima-Franco et al, 2001  ). In a different way, 
the CBA produced an initial 30% increase on the twitch 
tension in the ﬁ  rst 10  min incubation which progressively 
returned to baseline by 40  min. This facilitatory effect in 
cholinergic neurotransmission produced by CBA had been 
already shown in isolated preparation (  Oshima-Franco et al, 
2000  ), alone or in venom:CBA or toxin:CBA mixtures, in 
agreement with the present ﬁ  ndings. Recent study reported 
that the minimal concentration of heparin still able to pro-
duce facilitation on cholinergic neurotransmission (twitch 
tension increase) was 30 IU/ml, and that this concentration 
maintained the original ability to antagonize the neurotoxic 
effect of BthTX-I (  Rodrigues et al, 2004  ). In the current 
study, a concentration 30-fold-lower (1  IU/ml) sustained 
such capacity of minimizing the neurotoxic effect, not 
causing any facilitation, as required for the purpose of the 
present study. 
  However, the heparin protection against bothropic venom 
effects seems to be reversible at least   in vitro  . In the current 
study, we showed that addition of protamine sulfate to the 
incubation bath containing Bjssu plus heparin completely 
inhibits the LHC antagonism. On the other hand, when 
protamine sulfate is incubated with Bjssu alone a total and 
irreversible blockade of muscle twitch tension is installed 
(data not shown). These ﬁ  ndings give strong evidence that 
protamine forms a complex when in the bath with heparin. 
In contrast, when heparin is absent from bath protamine 
alone does not impede the neurotoxicity of Bjssu. Pro-
tamine, given its polycationic nature (  Ando et al, 1973  ), is 
able to form stable inactive complexes with heparin, there-
fore it has been used as a speciﬁ  c antidote for neutralizing 
the heparin anticoagulant effect (  Majerus et al, 1991  ). 
  Although accidents caused by   B. jararacussu   show no visi-
ble clinical signs of neurotoxicity, experimentally a number 
of   in vivo   or   in vitro   studies have shown that motor nerve 
ﬁ  bers or nerve terminals can be affected by its venom. It 
abolishes contractions caused by direct and indirect elec-
trical stimulation of skeletal muscle in mouse (  Vital Brazil, 
1966  ;   Heluany et al, 1992  ;   Oshima-Franco et al, 2000  ), 
chick (  Heluany et al, 1992  ) and frog (  Rodrigues-Simioni 
et al, 1983  ) neuromuscular preparations. These effects 
are reproduced by BthTX-I, a myotoxin which represents 
around 15% of total the venom (  Homsi-Brandeburgo et al, 
1988  ). A neurotoxic effect of Bjssu, also reproduced by 
a subfraction (13-15,000  Da) isolated from venom was 
detected in frog cutaneous pectoris nerve-muscle prepara-
tions, although the authors have concluded that the nerve 
terminal was not the prime site of action of the venom/
subfraction (  Rodrigues-Simioni et al, 1983  ). Agreeing with 
this, subsequent studies have given consistently focused on 
the preponderant myotoxic action of Bjssu and its major 
Lys-49 PLA  2   myotoxin (BthTX-I) (  Melo and Suarez-Kurtz, 
1988a  ;   Melo and Suarez-Kurtz, 1988b  ;   Oshima-Franco et al, 
2000  ;   Oshima-Franco et al, 2001  ;   Randazzo-Moura et al, 
2006  ). It was only when a concentration of BthTX-I, low 
enough that the neurotoxic effect cannot be concealed by 
the muscular one, that a pre-synaptic effect became evi-
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molecule heparan sulfate. All of them participate in impor-
tant biological processes. The interaction of GAGs with a 
bulk of cell and interstitial proteins, such as, growth factors, 
cytokines, cell adhesion molecules (  Gandhi and Mancera, 
2008  ), gives the dimension of their importance (  Conrad, 
1998  ). For instance, heparin is able to bind to extracellular 
matrix proteins, such as ﬁ   bronectin or vitronectin (  Lane 
and Adams, 1993  ;   Lomonte et al, 1994b  ;   Melo and Suarez-
Kurtz, 1988b ), leading to intracellular signalization triggered 
by ACh at the synaptic cleft and stability to tissue against 
toxic agents, among which could be candidates some com-
ponents of snake venoms. 
  In summary, this work showed that heparin, when used a 
low concentration has greater efﬁ  ciency than the commer-
cial bothropic antivenom (CBA) to neutralize the neuro-
toxic activity of the   Bothrops jararacussu   venom and its 
major toxin  .   Low heparin concentration (LHC) paralleled 
in efﬁ   ciency to CBA against the tissue damage caused 
by venom but was lesser efﬁ  cient in relation to the toxin. 
Also, heparin paralleled to CBA in antagonizing the release 
of CK promoted by the toxin, but was less effective in 
antagoni  zing against the crude venom. The highest negative 
charge density of any known biological molecule (  Cox and 
Lenninger, 2004 ) endows heparin binding to a high number of 
positively-charged molecules. Our study showed a novel 
ﬁ  nding, the principal myotoxin of   B. jararacussu   venom, 
the basic Lys-49 PLA  2   BthTX-I, is not the only target for 
heparin antagonism. Possible interactions of heparin with 
synaptic molecules and basic proteins of the extra  cellular 
matrix of the endomysium are discussed. Some of the 
differences seen in heparin effects whether used in low or 
high concentration are unclear.     
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